Business
Dicot Pharma publishes prospectus in connection with the forthcoming rights issue
Dicot Pharma publishes prospectus in connection with the forthcoming rights issue
About this update from Dicot Pharma Ab
Dicot Pharma AB ("Dicot Pharma" or the "Company") today, on May 19, 2026, publishes an EU Follow-on Prospectus (the "Prospectus") in connection with the rights issue of units, consisting of shares and warrants ("Units"), of approximately SEK 210 million, resolved by the Board of Directors on May 8, 2026, pursuant to the authorisation granted by the Annual General Meeting on May 6, 2026, (the "Rights Issue"). The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen).NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.The ProspectusThe Prospectus has been prepared in connection with the forthcoming Rights Issue and has today, on May 19, 2026, been approved and registered by Finansinspektionen. The Prospectus, containing the complete terms and conditions, is available on the Company's website (www.dicotpharma.com) and will also be available on the website of Finansinspektionen (www.fi.se).Preliminary timetable for the Rights Issue (all dates refer to 2026 unless otherwise stated)May 21 - June 1: Trading in subscription rights on Nasdaq First North Growth MarketMay 21 - June 4: Subscription period in the Rights IssueMay 21 - June 24: Estimated trading in paid subscribed Units (BTU) on Nasdaq First North Growth MarketJune 8: Estimated date for announcement of the outcome of the Rights IssueJune 15 - June 19: Registration of the Rights Issue with the Swedish Companies Registration Office (Bolagsverket)May 10, 2027 - May 24, 2027: Exercise period for warrants of series TO 7AdvisersCorpura Fondkommission AB is acting as Sole Global Coordinator and Sole Bookrunner in connection with the Issue. Advokatfirman Lindahl KB is acting as legal adviser to the Company.Important informationThe information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Dicot Pharma. No action has been taken and no action will be taken to permit a public offering in any jurisdiction other than Sweden. An invitation...